Brief Reports
Copyright ©2005 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 28, 2005; 11(8): 1187-1192
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1187
IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab
Elena Urcelay, Juan Luis Mendoza, Alfonso Martínez, Laura Fernández, Carlos Taxonera, Manuel Díaz-Rubio, Emilio G. de la Concha
Elena Urcelay, Alfonso Martínez, Laura Fernández, Emilio G. de la Concha, Immunology Department, Hospital Universitario San Carlos, Madrid, Spain
Juan Luis Mendoza, Carlos Taxonera, Manuel Díaz-Rubio, Gastroenterology Department, Hospital Universitario San Carlos, Madrid, Spain
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Elena Urcelay, Immunology Department, Hospital Universitario San Carlos, Martin Lagos s/n, Madrid 28040, Spain.
Telephone: +34-913303347 Fax: +34-913303344
Received: September 7, 2004
Revised: September 9, 2004
Accepted: October 27, 2004
Published online: February 28, 2005

AIM: Inflammatory bowel diseases (IBD) are multifactorial pathologies of unknown etiology. One susceptibility locus, IBD5, has been mapped to chromosome 5q31. We analyzed our Spanish cohorts of Crohn’s disease (CD) and ulcerative colitis (UC) patients to determine whether this locus is associated with IBD, and to ascertain the main clinical phenotype influenced by this risk factor. The kind of interaction, either genetic heterogeneity or epistasis, between this IBD5 susceptibility region and the NOD2/CARD15 gene mutations was studied as well. Finally, we assessed whether this locus can predict response to infliximab therapy.

METHODS: A case control study was performed with 274 CD and 211 UC patients recruited from a single center and 511 healthy ethnically matched controls. Two polymorphisms were genotyped in the IBD5 locus and three in the CARD15/NOD2 gene.

RESULTS: Our results evidence association only with CD especially with the fistulizing phenotype and in the absence of NOD2/CARD15 variants (mutant allele frequency in patients vs controls: OR = 2.03, 95% CI = 1.35-3.06, P<0.01). The frequency of the IBD5 homozygous mutant genotype significantly increased in CD patients lacking response to infliximab (RR = 3.88, 95% CI = 1.18-12.0, P<0.05). UC patients overall do not show association with 5q31 polymorphisms, although a similar trend to the one observed in CD is found within the worse prognosis group.

CONCLUSION: The IBD5 variants may enhance an individual carrier’s risk for CD, mainly in the absence of the NOD2/CARD15 mutations and in fistulizing patients. The data presented suggest the potential role of the 5q31 polymorphisms as markers of response to infliximab.

Keywords: Crohn’s disease, Ulcerative colitis, 5q31 polymorphisms, Infliximab